EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026

EyePoint, Inc.

2024-Q2 EPS reported -$1.13 revenue$21,161,000

Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.
Cash and investments $280.2M at June 30, 2024; expected to fund operations through Phase 3 wet AMD topline data in 2026.
Phase 3 LUGANO wet AMD trial on track for first patient dosing in 2024; LUCIA trial to follow shortly.
Positive 12-month DAVIO 2 data: DURAVYU non-inferior to aflibercept in visual acuity; majority supplement-free.
Phase 2 VERONA (DME) fully enrolled; topline data anticipated Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.